ClinicalTrials.gg
RecruitingNCT07179679Updated Dec 11, 2025

A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors

A Phase 1 interventional study of TQB2934 injection (subcutaneous injection) in Multiple Myeloma, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Recruiting at 14 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Planned enrollment
198th of 406
42 · median 40
Started
2025
with 54 others
Phase 1
151 of 448
73 open now
Primary completion
2027-10
later than 173 of 274 live
Registered
376th of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 198th largest by planned enrollment of the 406 interventional ones that give a count, is one of 55 that started in 2025, is one of 151 in phase 1, reaches primary completion later than 173 of the 274 other live ones, and was the 376th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

233 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

TQB2934 is an anti-Cluster of Differentiation 3 (CD3) (Early T Cell Marker)×B cell maturation antigen (BCMA) double-specific antibody,and the isoform is IgG1(Native Immunoglobulin G1), which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA(B cell maturation antigen) to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.

TQB2934 for injection (subcutaneous injection) is intended for the treatment of patients with multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subjects voluntarily joined the study, signed an form, and had good compliance;
  • 18 years old≤age≤75 years old (calculated based on the date of signing the informed consent); Performance Status (ECOG) score 0\~2 points; expected survival is greater than 12 weeks;
  • Subjects with multiple myeloma must meet: 1) have a diagnostic record and meet the International Myeloma Working Group (IMWG) diagnostic criteria; 2) there is a ; 3) Refractory Multiple Myeloma (RRMM) has received at least one , and at least one proteasome inhibitor (PI), an immunomodulator (IMiD) and a Cluster of Differentiation 38 (CD38) monoclonal antibody are refractory; 4) disease progression within 12 months after the last treatment or treatment;
  • Laboratory inspection standards that meet the program requirements;
  • Women of childbearing age should agree that effective must be adopted during the study period and within 6 months after the end of the study, and that serum or urine pregnancy tests will be negative within 7 days before the study enrollment; men should agree that effective contraception must be adopted within 6 months after the end of the study period;

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with amyloidosis, active plasma cell leukemia (PCL, peripheral plasma cell proportion ≥5%, or absolute peripheral plasma cell count ≥0.5×109/L), Fahrenheit macroglobulinemia (WM) or POEMS syndrome and other plasma cell tumors;
  • Have received hematopoietic stem cell transplantation within 1 year before the first medication, or have received autologous hematopoietic stem cell transplantation (ASCT) within 12 weeks before the first medication;
  • Those who are known to have invasion of meninges or central nervous system or are highly suspected of invasion of meninges or central nervous system but cannot be identified;
  • Have received CD3×BCMA dual anti-anti-treatment in the past;
  • Cumulative treatment of dexamethasone >160 mg or equivalent dose of other within 4 weeks before the first medication, or received targeted therapy, cytotoxic drugs or any antibody therapy within 3 weeks before the first medication, or received proteasome inhibitor therapy or radiotherapy within 2 weeks before the first medication, or received immunomodulatory therapy within 1 week before the first medication;
  • Those who have received Chinese patent medicine treatments within 2 weeks before the first medication have received National Medical Products Administration (NMPA) -approved drug instructions that clearly have anti-tumor indications;
  • Those who have a history of within 4 weeks before the first medication or plan to undergo live attenuated vaccination during the study period;
  • A person with a history of severe allergies of unknown causes, or known to be allergic to monoclonal antibody drugs or exogenous human immunoglobulin, or known to be allergic to TQB2934 for injection or in drug preparations;
  • Have appeared within 3 years before the first medication or are currently suffering from other malignant tumors;
  • Unrelieved toxic reactions above Common Terminology Criteria (CTC) AE level 1 caused by any previous treatment, excluding hair loss, fatigue and peripheral neuropathy;
  • Those who have received major surgical treatment, obvious traumatic injury or expected research treatment within 4 weeks before the first medication, or have long-term uncured wounds or fractures;
  • Arterial/venous thrombosis events occurred within 6 months before the first dose;
  • People with a history of abuse of psychotropic substances and cannot quit or have mental disorders, or suffer from epilepsy and need treatment;
  • Those with poor blood pressure control;
  • People with poor diabetes control;
  • People with severe bacterial, viral or systemic fungal infections that are active or uncontrollable within 4 weeks before the first medication;
  • People with hepatitis or decompensated cirrhosis;
  • People with active tuberculosis, a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonia, radioactive pneumonia that needs treatment, or active pneumonia with clinical symptoms;
  • People who have had or are currently suffering from asthma within 2 years before the first medication, or who have (COPD) and have a forceful exhalation volume () in the first second \<50% expected value;
  • Those who have had asthma within 2 years before the first medication or are currently suffering from asthma;
  • People suffering from major cardiovascular diseases;
  • Have a history of immunodeficiency;
  • According to the researcher's judgment, there are concomitant diseases that seriously endanger the safety of the subject or affect the completion of the study, or subjects who believe there are other reasons that are not suitable for enrollment;
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    TQB2934 injection (subcutaneous injection)

    Subcutaneous injection,40mg.60mg each time,Cycle 1-3, once a week,Cycle 4-6, once every 2 weeks, if reach PR and above remission after 6 cycles of administration, once every 4 weeks,28 days as a treatment cycle.

    Drug: TQB2934 injection (subcutaneous injection)

Interventions

  • TQB2934 is an anti-CD3(Early T Cell Marker)×BCMA (B cell maturation antigen)double-specific antibody,and the isoform is Native Immunoglobulin G1 ( IgG1), which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA(B cell maturation antigen) to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.

06

What researchers measure

Primary outcomes

  1. Peak time (Tmax)

    It refers to the time when TQB2934 (subcutaneous injection) is administered for injection to reach the maximum blood drug concentration.

    Time frame: Within 120 hours after administration

  2. Peak drug concentration (Cmax)

    It refers to the highest blood drug concentration after administration of TQB2934 (subcutaneous injection).

    Time frame: Within 120 hours after administration

  3. Area under the plasma concentration-time curve (AUC0-last)

    To characterize the pharmacokinetics of TQB2934 by assessment of area under the plasma concentration time curve.

    Time frame: Within 120 hours after administration

  4. Elimination half-life (t1/2)

    t1/2 is time it takes for the blood concentration of TQB2934 to drop by half.

    Time frame: Within 120 hours after administration

  5. Apparent clearance (CL)

    Apparent clearance (CL)

    Time frame: Within 120 hours after administration

  6. Adverse events(AEs)

    Incidence and severity of subjects with adverse events(AEs), Abnormal laboratory test value and serious adverse events

    Time frame: Up to 24 months

Secondary outcomes

  1. Overall response rate (ORR)

    Proportion of subjects with best response as Partial relief (PR), Very good partial relief (VGPR), Complete Response (CR), Strict Complete Response (sCR)

    Time frame: Up to 24 months

  2. Clinical benefit rate (CBR)

    Proportion of subjects with best response as Minor relief (MR), PR(Partial relief), VGPR(Very good partial relief), CR (Complete Response), sCR (Strict Complete Response)

    Time frame: Up to 24 months

  3. very good partial response rate (VGPR)

    Proportion of subjects whose best response is VGPR, CR, sCR;

    Time frame: Up to 24 months

  4. Complete Response (CR) Rate

    Proportion of subjects whose best response is CR

    Time frame: Up to 24 months

  5. Strict Complete Response (sCR)

    Proportion of subjects whose best response is sCR;

    Time frame: Up to 24 months

  6. Negative rate of minimal residual disease (MRD)

    The proportion of subjects with negative MRD (\<10-5, multicolor flow cytometry or next-generation sequencing) at any time point from the first administration of the trial drug to disease progression or before receiving new anti-tumor therapy;

    Time frame: Up to 24 months

  7. Duration of remission (DOR)

    For all subjects whose best response was PR, VGPR, CR, sCR, the time from the date of first achieving PR, VGPR, CR, sCR to the date of first definite disease progression or (any cause) death(whichever occurs first).

    Time frame: Up to 24 months

  8. Time to first remission (TTR)

    Among all the subjects whose best response is PR, VGPR, CR, sCR, the time from the first administration of the test drug to the date of the first PR and above remission.

    Time frame: Up to 24 months

  9. Progression-free survival (PFS)

    The time between the first dose of the trial drug and the date of first definite disease progression or death (from any cause), whichever occurs first.

    Time frame: Up to 24 months

  10. Overall survival (OS)

    Time from first dose of study drug to date of death from any cause.

    Time frame: Up to 24 months

  11. Antidrug antibody (ADA) incidence and changes over time

    Positive incidence of anti-drug antibodies and changes over time

    Time frame: Up to 24 months

07

Study locations

2 of 14 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Oct 2027, 22 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 22 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2025
First posted
Sep 18, 2025
StartActual
Dec 9, 2025
Primary completionEst.
Oct 2027
CompletionEst.
Jun 2028
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07179679
Responsible party
Sponsor
First posted
Sep 18, 2025
Start date
Dec 9, 2025
Primary completion
Oct 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Dec 11, 2025

Study contacts

Peng Liu, Doctor
Contact
Liu.peng@zs-hospital.sh.cn
021-60267405

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934

Start the discussion